Galderma Group AG Updates on Dermatology Product Performance and Market Activity

Interim Clinical Data for Sculptra and Restylane

On 9 April 2026, Galderma Group AG released interim results from two investigator‑initiated trials (IITs) that evaluate the use of Sculptra and Restylane Skinboosters in women undergoing menopause and in patients experiencing aesthetic changes associated with weight‑loss medications. The six‑month trial, supported by Galderma, showed that the combination of Restylane Skinboosters with Sculptra produced clinically meaningful improvements in facial volume and skin texture. The data underline the products’ role in counteracting the volume loss and skin laxity that can accompany hormonal changes and weight management therapies. The company indicated that the trial will continue for a full 12 months, with final results expected later in 2026.

Launch of ALASTIN Signature Practice

Earlier on 7 April 2026, Galderma announced the launch of the first ALASTIN Signature Practice in partnership with leading aesthetic practices in the United States. The initiative marks the beginning of a planned roll‑out of ALASTIN Signature Practices across the U.S. in 2026. ALASTIN, a regenerative, peri‑procedural skincare product, has been marketed for several years; the new Signature Practice model seeks to provide a structured, high‑quality service experience for patients receiving peri‑procedural treatments. Galderma’s partnership with established aesthetic practices aims to elevate the standard of care and to expand the product’s market presence.

Market Context and Share Performance

The Swiss market closed lower on 7 April 2026, with the Swiss Market Index (SLI) recording a decline of approximately 1.4 % to 2 070 points. The downturn was attributed to geopolitical concerns surrounding the U.S.–Iran conflict and uncertainty ahead of the U.S. presidential election cycle.

Galderma Group AG’s shares were priced at CHF 156.6 on 7 April 2026, following a recent 52‑week high of CHF 170.1 and a 52‑week low of CHF 73.1. The company’s market capitalization stands at roughly CHF 36.8 billion, and its price‑earnings ratio is 77.57. The company’s focus on dermatology, including injectable aesthetics, therapeutic dermatology, and skincare, continues to position it as a significant player in the health‑care sector.

Outlook

Galderma’s ongoing trials for Sculptra and Restylane Skinboosters and the expansion of the ALASTIN Signature Practice model are expected to reinforce the company’s leadership in dermatological aesthetics. Investors and market participants will likely monitor the forthcoming trial results and the rollout progress of the ALASTIN Signature Practices for further insights into the company’s growth trajectory.